natgillin/translations-raw huggingface dataset:
Pregnancy and breast-feeding Rebetol must not be used by a girl or woman who is pregnant (see “Take special care with Rebetol”).
Nosečnost in dojenje Noseča dekleta ali ženske ne smejo jemati zdravila Rebetol (glejte poglavje “ Bodite posebno pozorni pri uporabi zdravila Rebetol ”).
Rebetol must not be used by a female who is breast-feeding a baby.
Doječe matere ne smejo jemati zdravila Rebetol.
Driving and using machines Rebetol does not affect your ability to drive or use machines; however, interferon alfa-2b may have an effect.
Vpliv na sposobnost upravljanja vozil in strojev Zdravilo Rebetol ne vpliva na vašo sposobnost za vožnjo ali upravljanje s stroji, medtem ko ima interferon alfa- 2b lahko določen vpliv.
Important information about some of the ingredients of Rebetol 40 mg/ml oral solution This medicinal product contains sucrose and sorbitol.
Pomembne informacije o nekaterih sestavinah zdravila Rebetol 40 mg/ ml peroralna raztopina To zdravilo vsebuje saharozo in sorbitol.
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.
Če vam je zdravnik povedal, da ne prenašate nekaterih sladkorjev, se morate pred jemanjem tega zdravila posvetovati s svojim zdravnikom.
Your doctor may adjust the dose and the length of time to take this treatment according to the response.
66 Zdravnik je določil ustrezen odmerek zdravila Rebetol za vas ali vašega otroka na podlagi telesne mase, lahko pa bo pozneje prilagodil odmerek in dolžino zdravljenja glede na vaš odziv nanj.
Blood tests will be done regularly to help the doctor to know if this treatment is working.
Redno boste opravljali krvne preiskave, da bo zdravnik ugotovil, ali je zdravljenje pri vas učinkovito.
Depending upon the results of these tests, your doctor may change the dose to be taken.
Glede na izvide teh preiskav bo lahko spremenil odmerek zdravila Rebetol.
If severe kidney or liver problems develop, this treatment will be stopped.
Če se pojavijo hude težave z ledvicami ali jetri, bo zdravljenje ustavljeno.
Rebetol oral solution:
Rebetol peroralna raztopina:
If you are giving this medicine to a child, the doctor will tell you how much to give for each dose.
Če to zdravilo dajete otroku, vam bo zdravnik povedal, koliko mililitrov morate dati za vsak odmerek.
The usual dose, according to how much the patient weighs, is shown in the table below.
Običajni odmerki glede na telesno maso bolnika so podani v spodnji preglednici.
63 To use this table, look for the line that shows how much the patient weighs.
Pri uporabi te preglednice poiščite vrstico, v kateri je navedena bolnikova telesna masa.
Then read across on the same line to see the how much to measure for the usual morning and evening doses.
Potem v isti vrstici na desni strani odberite običajni jutranji ali večerni odmerek.
If your doctor’s instructions are different from the amounts on the table, follow your doctor’s instructions.
Če se navodila vašega zdravnika razlikujejo od podatkov v preglednici, upoštevajte zdravnikova navodila.
If you have any questions about the dose, ask your doctor.
Če imate kakršnakoli vprašanja o odmerku, se posvetujte s svojim zdravnikom.
Rebetol oral solution Usual Dosage in Children If the patient weighs Measure and give this dose
Rebetol peroralna raztopina
Morning Dose Evening Dose 2 ml 2 ml 3 ml 2 ml 3 ml 3 ml 4 ml 3 ml 4 ml 4 ml 5 ml 4 ml 5 ml 5 ml 6 ml 5 ml 6 ml 6 ml 7 ml 6 ml 7 ml 7 ml 8 ml 7 ml 8 ml 8 ml 9 ml 8 ml
2 ml 2 ml 3 ml 3 ml 4 ml 4 ml 5 ml 5 ml 6 ml 6 ml 7 ml 7 ml 8 ml 8 ml
The plastic oral dosing syringe consists of two parts, an opaque barrel, and a white plunger rod that fits into the barrel.
Plastična brizga za peroralno odmerjanje je sestavljena iz dveh delov – neprozornega valjastega dela in belega bata, ki se tesno prilega valjastemu delu.
The rod is marked with 0.5 ml markings starting at 1.5 ml (at the very top of the rod) and ending at 10 ml.
Bat ima oznake z razmiki po 0, 5 ml, v razponu od 1, 5 ml (čisto na vrhu bata) do 10 ml.
You can measure the dose with the oral dosing syringe provided
Odmerek lahko izmerite s priloženo brizgo za peroralno odmerjanje, kot je opisano v nadaljevanju.
Insert the assembled dosing syringe into the bottle of Rebetol oral solution.
Vstavite sestavljeno brizgo za peroralno odmerjanje v stekleničko zdravila Rebetol peroralna raztopina.
While keeping the tip in the liquid, pull the rod out.
67 Vrh brizge držite v tekočini in medtem vlecite bat iz brizge.
As the solution fills the syringe, you will see the numbers on the rod go up, such as 1.5 ml, 2.0 ml, 2.5 ml, etc.
1, 5 ml, 2, 0 ml, 2, 5 ml itn.
Pull the rod out until you can read the correct number of ml for the dose you are measuring.
Potegnite bat ven, da boste lahko prebrali pravilno število mililitrov za odmerek, ki ga želite dati bolniku.
Take the oral syringe out of the bottle and check to see that the correct amount appears in the bottom of the syringe.
Vzemite brizgo za peroralno odmerjanje iz stekleničke in preverite, ali na dnu brizge vidite pravilno količino raztopine.
64 Hold the syringe to your mouth and release the dose into your mouth (or the mouth of the patient you are caring for) by pushing in the rod.
Brizgo držite pri ustih in s pritiskom na bat izpustite odmerek v usta (svoja ali bolnikova).
Swallow the dose.
Pogoltnite odmerek oz. bolnik naj pogoltne odmerek.
If it does, rinse it with water before inserting it in the bottle again.
Če se to kljub temu zgodi, brizgo sperite z vodo, preden jo boste spet vstavili v stekleničko.
The syringe should be rinsed with water after each use to avoid stickiness.
Brizgo sperite z vodo po vsaki uporabi, da ne bi postala lepljiva.
Take or give the prescribed dose by mouth in the morning and evening, with a meal.
Predpisani odmerek zaužijte oz. dajte bolniku peroralno s hrano, zjutraj in zvečer.
Rebetol oral solution is used in combination with interferon alfa-2b for injection.
Zdravilo Rebetol se uporablja v kombinaciji z interferonom alfa- 2b za injiciranje.
For complete information be sure to read the “How to take” section of the Package Leaflet for interferon alfa-2b.
Za popolnejše informacije morate prebrati tudi poglavje “ Kako uporabljati zdravilo ” v navodilu za uporabo za interferon alfa- 2b.
Interferon alfa-2b for subcutaneous use:
Interferon alfa- 2b za subkutano uporabo:
In children and adolescents, the usual dose is 3 million IU/m2 three times a week, every other day, injected subcutaneously (under the skin).
Pri otrocih in mladostnikih je običajen odmerek 3 milijone i. e. / m2 trikrat na teden, vsak drugi dan, s subkutano (podkožno) injekcijo.
It is given three times a week, every other day; for example, on Monday, Wednesday and Friday.
Zdravilo dajemo trikrat na teden, vsak drugi dan, npr. v ponedeljek, sredo in petek.
Interferons may cause unusual tiredness; if you are injecting this medicine yourself or giving it to a child, use it at bedtime.
Če si zdravilo injicirate sami ali če ga dajete otroku, ga dajte pred spanjem.
Most patients are treated for 6 to 12 months with the combination of Rebetol and interferon alfa-2b.
Pri večini bolnikov traja zdravljenje s kombinacijo zdravila Rebetol in interferona alfa- 2b od 6 do 12 mesecev.
However, at the end of 6 months of treatment, your doctor will decide if the treatment will be continued for the full 12 months.
Po koncu 6- mesečnega zdravljenja bo vaš zdravnik določil, ali boste z zdravljenjem nadaljevali do polnih 12 mesecev.
Always take Rebetol exactly as your doctor has told you.
68 Pri uporabi zdravila Rebetol natančno upoštevajte zdravnikova navodila.
If you take more Rebetol th an you should Tell your doctor or pharmacist as soon as possible.
Če ste vzeli večji odmerek zdravila Rebetol, kot bi smeli Čimprej obvestite svojega zdravnika ali farmacevta.
Also, be sure to read the “Possible side effects” section of the Package Leaflet for interferon alfa-2b.
Prebrati morate tudi poglavje “ Možni neželeni učinki ” v navodilu za uporabo za interferon alfa- 2b.
65 Like all medicines, Rebetol used in combination with an alpha interferon product can cause side effects, although not everybody gets them.
Kot vsa zdravila ima lahko tudi zdravilo Rebetol v kombinaciji z zdravilom z interferonom alfa neželene učinke, ki pa se ne pojavijo pri vseh bolnikih.
The following side effects have occurred with the combination of Rebetol and interferon alfa-2b in children and adolescents:
Pri odraslih so se pojavili naslednji neželeni učinki pri kombiniranem zdravljenju z zdraviloma Rebetol kapsule in zdravilom z interferonom alfa.
Very commonly reported side effects (at least 1 in every 10 patients): irritation or redness at the site of injection, headache, tired feeling, shaking chills, fever, flu-like symptoms, dizziness, nausea, loss of appetite, diarrhoea, stomach pain, vomiting, muscle aches, pain in joints and muscles, feeling depressed or irritable, trouble falling asleep or staying asleep, mood swings, virus infection, hair loss, rash, pharyngitis (sore throat), decrease in the number of red blood cells or decrease in certain white blood cells called neutrophils that fight infection, change in thyroid gland activity (which may make you feel tired or, less commonly, energetic), feeling unwell, and decrease in their rate of growth (height and weight).
Zelo pogosto prijavljeni neželeni učinki (pri najmanj 1 na 10 bolnikov): zvišana telesna temperatura, gripi podobni simptomi, omotica, slabost, izguba teka, driska, želodčne bolečine, bruhanje, mišične bolečine, bolečine v sklepih in mišicah, depresivnost in razdražljivost, nezmožnost zaspati ali zbujanje ponoči, nihanje razpoloženja, virusne okužbe, izpadanje las, izpuščaj, faringitis (vnetje žrela), zmanjšanje števila rdečih krvničk ali določenih belih krvničk, ki jih imenujemo nevtrofilci in se bojujejo proti okužbam, spremembe delovanja žleze ščitnice (zaradi katerih lahko postanete utrujeni, redkeje pa polni energije), slabo počutje in upočasnitev rasti (telesne višine in mase).
rapid heart rate, low or high blood pressure, palpitations (pounding heart beat), puffy or swollen hands and ankles, feeling faint, migraine, tense muscles, arthritis, unsteady when walking, vertigo (spinning feeling), changes in your hearing, ringing in ears, earache, blurred vision, mental disorder, abnormal crying, enlarged liver, jaundice (yellow skin), change in taste, taste loss, dry mouth, bleeding gums, inflamed gums, thirst, intestinal gas (flatus), irritated colon, passing more urine than usual, abnormal urine, painful menstruation, disorder of ovary, breast pain, lack of interest in sex or inability to perform, irritation of prostate gland, sinusitis, nonproductive cough, difficult breathing, abnormal hair texture, psoriasis, cardiac murmur (abnormal heart beat sounds), excess of sugar in the blood, low calcium level in the blood, and water impairment.
Naslednji dodatni pogosto prijavljeni neželeni učinki (pri najmanj 1 na 100 bolnikov, vendar pri manj kot 1 na 10 bolnikov) so se pojavili pri uporabi kombinacije zdravila Rebetol in zdravila interferon alfa pri odraslih, vendar ne pri otrocih: pospešen srčni utrip, nizek ali visok krvni tlak, palpitacije (razbijanje srca), nabrekle ali otekle dlani ali gležnji, občutek slabosti, migrena, napete mišice, artritis, negotova hoja, vertigo (vrtoglavica), spremembe sluha, zvonjenje v ušesu, ušesne bolečine, zamegljen vid, duševne motnje, nenormalen jok, povečana jetra, zlatenica (rumenica kože), spremembe okusa, izguba čuta za okus, suha usta, krvavitve dlesni, vnetje dlesni, žeja, plini v črevesju (napenjanje), razdraženo debelo črevo, odvajanje več seča kot običajno, nenormalen seč, boleče menstruacije, bolezni jajčnikov, bolečine v dojkah, pomanjkanje zanimanja za spolnost ali impotenca, draženje prostate, sinusitis, neproduktiven kašelj, težave z dihanjem, nenormalna tekstura las, psoriaza, šum na srcu (nenormalni srčni toni), preveč sladkorja v krvi, nizka koncentracija kalcija v krvi in motnje ravnovesja vode.
Rebetol in combination with an alpha interferon product may also cause aplastic anaemia, pure red cell aplasia (a condition where the body stopped or reduced the production of red blood cells); this causes severe anaemia, symptoms of which would include unusual tiredness and a lack of energy, seizure (convulsions), inflammation of the pancreas, severe rashes which may be associated with blisters in the mouth, nose, eyes and other mucosal membranes (erythema multiforme, Stevens Johnson syndrome), and toxic epidermal necrolysis (blistering and peeling of the top layer of skin).
Ta motnja povzroči hudo anemijo, med njene simptome pa sodijo neobičajna utrujenost in pomanjkanje energije, epileptične napade (konvulzije), vnetje trebušne slinavke, hud izpuščaj, ki je lahko združen s pojavom mehurjev v ustih, nosu, očeh in na drugih sluznicah (multiformni eritem, Stevens- Johnsonov sindrom), toksično epidermalno nekrolizo (mehurjenje in luščenje povrhnje plasti kože).
Rebetol in combination with peginterferon alfa-2b or interferon alfa-2b may also cause: loss of use, drooping or loss of power of facial muscles, loss of feeling sensation, loss of consciousness, loss of vision, difficulty breathing, changes in the way your heart beats, chest pain, pain down left arm, jaw pain, dark, cloudy or abnormally coloured urine.
Zdravilo Rebetol v kombinaciji s peginterferonom alfa- 2b ali interferonom alfa- 2b lahko povzroči še povešenost obraznih mišic, izgubo funkcije ali njihovo šibkost, izgubo telesnih občutkov, izgubo zavesti, izgubo vida, težave z dihanjem, spremembe srčnega utripa, bolečine v prsih, bolečine, ki izžarevajo navzdol po levi roki, bolečine v čeljustih in temen,
You or your caregiver should call your doctor immediately if you have any of these symptoms.
70 moten ali nenormalno obarvan seč.
Diabetes and pneumonia have been reported rarely.
Če imate katerega od teh simptomov, morate vi ali vaš negovalec nemudoma poklicati vašega zdravnika.
If you are receiving nucleoside reverse transcriptase inhibitor (NRTI) treatment, the addition of Rebetol and interferon alfa-2b may increase your risk of lactic acidosis and liver failure.
Če se zdravite z zaviralcem nukleozidne reverzne transkriptaze (NRTI), bi lahko dodatek zdravila Rebetol in interferona alfa- 2b povečal tveganje za nastanek laktacidoze in jetrne odpovedi.
Do not use Rebetol after the expiry date which is stated on the label.
Shranjujte pri temperaturi do 30 ºC.
67 Do not use Rebetol without advice of your doctor or pharmacist if you notice any change in the appearance of the solution.
Ne uporabljate zdravila Rebetol, ne da bi se posvetovali s svojim zdravnikom ali farmacevtom, če opazite kakršnekoli spremembe videza raztopine.
- The active substance is ribavirin 40 mg/ml.
- Zdravilna učinkovina je ribavirin 40 mg/ ml.
Sodium citrate, citric acid, anhydrous, sodium benzoate, glycerol,
- Pomožne snovi so natrijev citrat, brezvodna citronska kislina, natrijev benzoat, glicerol, saharoza,
sucrose, sorbitol liquid (crystallising), propylene glycol, purified water, natural and artificial bubble gum flavouring
tekoči sorbitol (kristalizirajoči), propilenglikol, prečiščena voda, naravna in umetna aroma za žvečilne gumije
Rebetol 40 mg/ml oral solution is packaged in 118 ml size amber glass bottles containing 100 ml of oral solution.
Rebetol 40 mg/ ml peroralna raztopina je pakirana v 118 ml stekleničke iz stekla jantarne barve, ki vsebujejo po 100 ml peroralne raztopine.
A 10 ml oral dosing syringe is provided to measure the dose.
Priložena je tudi 10 ml peroralna odmerna brizga za merjenje odmerka.
SP Europe
SP Europe 73, rue de Stalle B- 1180 Bruxelles Belgija
България Шеринг-Плау Сентрал Ийст Клон България Ийст Трейд Парк Център Бул.
71 Шеринг- Плау Сентрал Ийст Клон България Ийст Трейд Парк Център Бул.
Tlf: + 47 67 16 64 50
Norge Pb. 398 N- 1326 Lysaker Tlf: + 47 67 16 64 50
Italia Via fratelli Cervi snc, Centro Direzionale Milano Due Palazzo Borromini I-20090 Segrate (Milano) Tel: + 39-02 2101 8.1
Italia Via fratelli Cervi snc, Centro Direzionale Milano Due
69 This leaflet was last approved on
Navodilo je bilo odobreno
Rebif is a solution for injection in pre-filled syringes and cartridges.
Zdravilo Rebif je raztopina za injiciranje v predhodno napolnjenih brizgah in vložkih.
The syringes contain 8.8, 22 or 44 micrograms of the active substance, interferon beta-1a.
Brizge vsebujejo 8, 8, 22 ali 44 mikrogramov zdravilne učinkovine interferon beta- 1a.
The cartridges contain a total of 66 or 132 micrograms of interferon beta-1a and are designed for multiple dosing using an electronic injection device that delivers 8.8, 22 or 44 micrograms per dose.
Vložki vsebujejo skupno 66 ali 132 mikrogramov interferona beta- 1a in so zasnovane za večkratno odmerjanje z uporabo električne naprave za injiciranje, ki odmeri 8, 8, 22 ali 44 mikrogramov na odmerek.
Rebif is used to treat patients with relapsing multiple sclerosis (MS).
Zdravilo Rebif se uporablja za zdravljenje bolnikov, ki imajo multiplo sklerozo (MS) z zagoni.
This is the type of MS where the patient has attacks (relapses) within periods with no symptoms.
To je oblika multiple skleroze, pri kateri ima bolnik napade (zagone) med obdobji brez simptomov.
Its effectiveness has not been shown in patients with secondary progressive MS (the type of MS that comes after relapsing MS), when the disease is not in a relapsing phase.
Učinkovitost zdravila Rebif ni bila ugotovljena pri bolnikih s sekundarno progresivno multiplo sklerozo (obliko multiple skleroze, ki se razvije po multipli sklerozi z zagoni), ko se bolezen ne pojavlja več v zagonih.
Rebif should not be used in children aged below 12 years because of a lack of information on the use of the medicine in this group.
Zdravilo Rebif se ne sme uporabljati pri otrocih, mlajših od 12 let, zaradi pomanjkanja informacij o uporabi zdravila v tej skupini.
Rebif treatment should be started by a doctor who has experience in the management of MS.
Zdravljenje z zdravilom Rebif mora začeti zdravnik, ki ima izkušnje z zdravljenjem multiple skleroze.
The recommended dose of Rebif is 44 micrograms given three times a week by injection under the skin.
Priporočeni odmerek zdravila Rebif je 44 mikrogramov trikrat na teden v obliki podkožne injekcije.
The 22– microgram dose is recommended for patients who cannot tolerate the higher dose and for adolescents aged between 12 and 16 years.
Za bolnike, ki ne prenašajo višjega odmerka, in mladostnike, stare od 12 do 16 let, je priporočljivi odmerek zdravila Rebif z 22 mikrogramov zdravilne učinkovine.
When first starting treatment with Rebif, the dose should be slowly increased to avoid side effects, starting with 8.8 micrograms three times a week for the first two weeks, followed by 22 micrograms three times a week for the next two weeks.
Ob začetku zdravljenja z zdravilom Rebif je treba odmerek zviševati počasi, da preprečimo neželene učinke.
Special packs with the correct quantities of syringes or cartridges are available when starting treatment.
Začnemo z odmerkom 8, 8 mikrograma trikrat tedensko v obdobju prvih dveh tednov, sledi odmerek v višini 22 mikrogramov trikrat tedensko v obdobju naslednjih dveh tednov.
The electronic injection device used with the cartridges is programmed to deliver the correct doses of Rebif at the start of treatment and during the standard-dose phase.
Električna naprava za injiciranje, ki se uporablja z vložki, je programirana tako, da odmeri pravilne odmerke zdravila Rebif na začetku zdravljenja in med fazo s standardnim odmerkom.
The patients can inject Rebif themselves if they have been trained appropriately.
Bolniki si lahko zdravilo Rebif vbrizgajo sami, če so bili za to ustrezno usposobljeni.
The doctor may advise the patient to take a fever-reducing painkiller before each injection and for 24 hours after injection to reduce the flu-like symptoms that may occur as a side effect of treatment.
Zdravnik lahko bolniku svetuje, naj pred vsakim injiciranjem in 24 ur po injiciranju vzame protibolečinsko sredstvo za zniževanje povišane telesne temperature, da se ublažijo gripi podobni simptomi, ki se lahko pojavijo kot neželeni učinek zdravljenja.
MS is a disease of the nerves, in which inflammation destroys the protective sheath around the nerves.
Multipla skleroza je bolezen živčnega sistema, pri kateri vnetje uničuje zaščitno ovojnico okoli živcev.
This is called ‘ demyelination’.
Ta proces se imenuje demielinizacija.
The active substance in Rebif, interferon beta-1a, belongs to the group ‘ interferons’.
Zdravilna učinkovina zdravila Rebif, interferon beta- 1a, spada v skupino interferonov.
The exact way that Rebif works in MS is not yet known but interferon beta seems to calm the immune system down and prevent relapses of MS.
Natančen način delovanja zdravila Rebif pri multipli sklerozi še ni popolnoma znan, vendar vse kaže, da interferon beta pomirja imunski sistem in preprečuje zagone multiple skleroze.
Interferon beta-1a is produced by a method known as ‘ recombinant DNA technology’: it is made by a cell that has received a gene (DNA), which makes it able to produce interferon beta-1a.
Interferon beta- 1a je izdelan z metodo, imenovano „ tehnologija rekombinantne DNK “, pri kateri celica prejme gen (DNK), s katerim lahko tvori interferon beta- 1a.
The replacement interferon beta-1a acts in the same way as naturally produced interferon beta.
Nadomestni interferon beta- 1a deluje enako kot naravno proizvedeni interferon beta.
The patients had experienced at least two relapses in the previous two years.
Bolniki so imeli najmanj dva zagona v preteklih dveh letih.
Patients received either Rebif (22 or 44 micrograms) or placebo (a dummy treatment) for two years.
Bolniki so dve leti prejemali bodisi zdravilo Rebif (22 ali 44 mikrogramov) ali placebo (zdravilo brez zdravilne učinkovine).
The main measure of effectiveness was the number of relapses that the patients had.
Glavno merilo učinkovitosti je bilo število zagonov, ki so jih bolniki imeli.
The study looked at the effectiveness of the medicine in preventing the progression of disability over three years.
V študiji so raziskovali učinkovitost zdravila pri preprečevanju napredovanja nesposobnosti v treh letih.
The company has not carried out any formal studies of patients under 16 years of age.
Družba ni izvedla nobene uradne študije pri bolnikih, mlajših od 16 let.
However, it presented information from published studies on the use of Rebif in children aged between 12 and 18 years.
Je pa predstavila informacije iz objavljenih študij o uporabi zdravila Rebif pri otrocih, starih od 12 do 18 let.
Rebif was more effective than placebo in reducing the number of relapses in relapsing-remitting MS.
Zdravilo Rebif je bilo učinkovitejše od placeba pri zmanjševanju števila zagonov recidivno- remitentne multiple skleroze.
Relapses were reduced by about 30% over two years for both Rebif 22 and 44 micrograms compared with placebo, and by 22% (Rebif 22 micrograms) and 29% (Rebif 44 micrograms) over four years.
V dveh letih sta obliki zdravila Rebif v odmerku 22 in 44 mikrogramov vsaka zmanjšali število zagonov za 30% v primerjavi s placebom, v štirih letih pa za 22% (zdravilo Rebif v odmerku 22 mikrogramov) in 29% (zdravilo Rebif v odmerku 44 mikrogramov).
In the study of patients with progressive MS, Rebif had no significant effect on the progression of disability, but the relapse rate was reduced by about 30%.
V študiji z bolniki s progresivno multiplo sklerozo zdravljenje z zdravilom Rebif ni imelo večjega vpliva na napredovanje nesposobnosti, vendar se je stopnja zagonov znižala za približno 30%.
Some effect on progression of disability could be seen only in the patients who had relapses in the two years before the start of the study.
Nekaj učinkov na napredovanje nesposobnosti so opazili le pri tistih bolnikih, ki so imeli zagone dve leti pred začetkom študije.
In patients aged between 12 and 18, the published studies showed that the patients had a decrease in the rate of relapse.
Objavljene študije so pokazale, da je pri bolnikih, starih od 12 do 18 let, prišlo do zmanjšanja stopnje zagonov.
This may be due to Rebif treatment.
To je morda posledica zdravljenja z zdravilom Rebif.